Alpha Tau(DRTS) - 2022 Q4 - Annual Report

Exhibit 99.1 Alpha Tau Medical Announces Full Year 2022 Financial Results and Provides Corporate Update - Opened U.S. pivotal trial in recurrent cutaneous squamous cell carcinoma, which began enrolling patients in March - - Received Health Canada approval to initiate a liver cancer feasibility trial - -Pursued supply chain expansion in Israel, the U.S. and Japan, including increases in radioactive license capacities - - Cash & equivalents balance of $105.4 million, with runway for at least two years - JERUS ...